BG105250A - Means for reducing apoptosis - Google Patents

Means for reducing apoptosis

Info

Publication number
BG105250A
BG105250A BG105250A BG10525001A BG105250A BG 105250 A BG105250 A BG 105250A BG 105250 A BG105250 A BG 105250A BG 10525001 A BG10525001 A BG 10525001A BG 105250 A BG105250 A BG 105250A
Authority
BG
Bulgaria
Prior art keywords
cells
reducing apoptosis
apoptosis
reducing
administered
Prior art date
Application number
BG105250A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michel BRIL Antoine
Robin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Laboratoires Pharmaceutiques S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Laboratoires Pharmaceutiques S.A.S. filed Critical Smithkline Beecham Plc
Publication of BG105250A publication Critical patent/BG105250A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG105250A 1998-07-21 2001-02-14 Means for reducing apoptosis BG105250A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
BG105250A true BG105250A (en) 2001-11-30

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105250A BG105250A (en) 1998-07-21 2001-02-14 Means for reducing apoptosis

Country Status (26)

Country Link
EP (2) EP1516617A2 (de)
JP (1) JP2002521326A (de)
KR (1) KR20010079551A (de)
CN (1) CN1310620A (de)
AP (1) AP2001002036A0 (de)
AT (1) ATE288746T1 (de)
AU (1) AU5053799A (de)
BG (1) BG105250A (de)
BR (1) BR9912117A (de)
CA (1) CA2338211A1 (de)
DE (1) DE69923687T2 (de)
DK (1) DK1098639T3 (de)
EA (1) EA200100165A1 (de)
ES (1) ES2237929T3 (de)
HK (1) HK1037865A1 (de)
HU (1) HUP0103199A3 (de)
ID (1) ID26986A (de)
IL (1) IL140664A0 (de)
NO (1) NO20010292L (de)
OA (1) OA11579A (de)
PL (1) PL345627A1 (de)
PT (1) PT1098639E (de)
SI (1) SI1098639T1 (de)
SK (1) SK1012001A3 (de)
TR (1) TR200100207T2 (de)
WO (1) WO2000004890A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
SI1098639T1 (de) 2005-08-31
NO20010292D0 (no) 2001-01-18
EA200100165A1 (ru) 2001-08-27
CN1310620A (zh) 2001-08-29
ES2237929T3 (es) 2005-08-01
EP1098639A1 (de) 2001-05-16
PL345627A1 (en) 2002-01-02
HK1037865A1 (en) 2002-02-22
AU5053799A (en) 2000-02-14
BR9912117A (pt) 2001-04-10
DE69923687D1 (de) 2005-03-17
DK1098639T3 (da) 2005-06-13
EP1098639B1 (de) 2005-02-09
WO2000004890A1 (en) 2000-02-03
ID26986A (id) 2001-02-22
DE69923687T2 (de) 2006-04-06
PT1098639E (pt) 2005-06-30
OA11579A (en) 2004-06-01
AP2001002036A0 (en) 2001-03-31
IL140664A0 (en) 2002-02-10
HUP0103199A2 (hu) 2002-05-29
SK1012001A3 (en) 2001-08-06
KR20010079551A (ko) 2001-08-22
CA2338211A1 (en) 2000-02-03
EP1516617A2 (de) 2005-03-23
NO20010292L (no) 2001-03-08
JP2002521326A (ja) 2002-07-16
TR200100207T2 (tr) 2001-05-21
ATE288746T1 (de) 2005-02-15
HUP0103199A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
WO1996023065A3 (en) Inhibition of neovascularization using vegf-specific oligonucleotides
PL341300A1 (en) Non-dissolvable compositions for monitoring glucose level in blood
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
OA08138A (en) Disinfection method and composition therefor.
IL124557A0 (en) Compositions for reducing blood glucose and/or inhibiting the activity of cgrp
HK1041436A1 (en) Use of nicotinic acid derivatives for the treatment of dna damae in skin cells.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
HK1046863A1 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
EP0198092A4 (de) Oberflächlich behandeltes magnesium oder dessen legierungen und verfahren zum oberflächenbehandeln.
ES2088771A1 (es) Metodo para mejorar la acividad reproductora en verracos utilizando alimento para los verracos reproductores.
EP0671768A3 (de) Verbesserungen in oder in Bezug auf Elektroden für LSI.
MX9703944A (es) Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis.
UA37199C2 (uk) Алкіламінокетони
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
BG105250A (en) Means for reducing apoptosis
MY120530A (en) Combination preparation for use in dementia
EP1089731A4 (de) Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel
EP0349589A4 (de) Pharmakologisch aktive cholinerge zubereitungen und verfahren zur herstellung und deren verwendung zur behandlung von krankheiten.
PL328948A1 (en) Autism treating method
GB8909428D0 (en) Improvements in and relating to arch supporting insoles
HK1025558A1 (en) Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
PL328924A1 (en) Method of treating abuse of substances
BG105251A (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart